Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Journal of neurology·2026
Same author

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

CNS drugs·2026
Same author

Prevalence and clinical implications of abnormal autoantibodies in Omani patients with multiple sclerosis: A retrospective cross-sectional study.

Multiple sclerosis and related disorders·2026
Same author

The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Neurology·2026
Same journal

Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials.

Postgraduate medical journal·2026
Same journal

Two cases of toxic epidermal necrolysis with severe ocular involvement treated with adjunctive tofacitinib.

Postgraduate medical journal·2026
Same journal

Diastolic dysfunction and diabetes: the DIADAD study-a retrospective cohort study from Liverpool.

Postgraduate medical journal·2026
Same journal

Care, cash, and proof: forensic accountability for war-related starvation.

Postgraduate medical journal·2026
Same journal

Response to traumatic injuries in polo players in England.

Postgraduate medical journal·2026
Same journal

Aids to venesection and parenteral drug administration in patients with difficult veins.

Postgraduate medical journal·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Neuromyelitis optica: an overview.

R Nandhagopal1, Abdullah Al-Asmi, Arunodaya R Gujjar

  • 1Neurology Unit, Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University Hospital, Al Khod, Oman. rnandagopal@yahoo.com

Postgraduate Medical Journal
|March 19, 2010
PubMed
Summary
This summary is machine-generated.

Neuromyelitis optica (NMO) is an autoimmune disorder affecting the central nervous system. Early diagnosis and long-term immunosuppression are crucial for managing NMO and preventing relapses.

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Related Experiment Videos

Last Updated: Jun 15, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Area of Science:

  • Neuroimmunology
  • Autoimmune Disorders
  • Central Nervous System Inflammation

Background:

  • Neuromyelitis optica (NMO) is a relapsing inflammatory condition of the central nervous system, often mistaken for multiple sclerosis.
  • Recent understanding has expanded the clinical spectrum of NMO, including limited forms and associations with other autoimmune diseases.
  • Cerebral lesions may be present in NMO and do not exclude the diagnosis.

Purpose of the Study:

  • To review current knowledge on neuromyelitis optica (NMO).
  • To discuss epidemiology, clinical presentation, immunopathology, diagnosis, and management of NMO.
  • To differentiate NMO from multiple sclerosis.

Main Methods:

  • Review of recent literature on neuromyelitis optica.
  • Analysis of clinical, radiological, and laboratory findings.
  • Discussion of immunopathology, particularly the role of aquaporin 4 antibodies.

Main Results:

  • Aquaporin 4 antibody is a key pathogenetic factor and diagnostic marker for NMO, classifying it as an autoimmune channelopathy.
  • Longitudinally extensive myelitis on spinal MRI supports the diagnosis in the appropriate clinical context.
  • NMO differs from multiple sclerosis based on clinical, radiological, and laboratory data.

Conclusions:

  • NMO requires distinct diagnostic and management strategies compared to multiple sclerosis.
  • Relapse prevention through long-term immunosuppressive therapy is the primary goal in managing NMO.
  • Understanding the immunopathology, including the role of aquaporin 4 antibodies, is vital for effective NMO treatment.